M
Mark L. Ormiston
Researcher at Queen's University
Publications - 21
Citations - 1173
Mark L. Ormiston is an academic researcher from Queen's University. The author has contributed to research in topics: Pulmonary hypertension & BMPR2. The author has an hindex of 10, co-authored 21 publications receiving 686 citations.
Papers
More filters
Journal ArticleDOI
Pulmonary arterial hypertension: pathogenesis and clinical management.
TL;DR: Patients with PAH have dyspnea, reduced exercise capacity, exertional syncope, and premature death from right ventricular failure, and targeted therapies, used alone or in combination, improve functional capacity and hemodynamics and reduce hospital admissions.
Journal ArticleDOI
Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2.
Paola Caruso,Benjamin J. Dunmore,Kenny Schlosser,Sandra Schoors,Claudia Dos Santos,Carol Perez-Iratxeta,Jessie R. Lavoie,Hui Zhang,Lu Long,Amanda Flockton,Maria G. Frid,Paul D. Upton,Angelo D'Alessandro,Charaka Hadinnapola,Fedir Kiskin,Mohamad Taha,Liam A. Hurst,Mark L. Ormiston,Akiko Hata,Kurt R. Stenmark,Peter Carmeliet,Duncan J. Stewart,Nicholas W. Morrell +22 more
TL;DR: In this paper, the authors examined the miRNA and proteomic profiles of blood outgrowth endothelial cells (BOECs) from patients with heritable pulmonary arterial hypertension (PAH) caused by mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene and patients with idiopathic PAH to determine mechanisms underlying abnormal endothelial glycolysis.
Journal ArticleDOI
MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype
Zhigang Hong,Kuang-Hueih Chen,Asish Dasgupta,François Potus,Kimberly J. Dunham-Snary,Sébastien Bonnet,Lian Tian,Jennifer Fu,Sandra Breuils-Bonnet,Steeve Provencher,Danchen Wu,Jeffrey Mewburn,Mark L. Ormiston,Stephen L. Archer +13 more
TL;DR: In this paper, the pore-forming subunit, MCU, was manipulated through small interfering RNA knockdown or MCU plasmid-mediated up-regulation, as well as through modulation of the upstream microRNAs (miRs) miR-138 and miR25.
Journal ArticleDOI
Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications.
Kuang-Hueih Chen,Asish Dasgupta,Jianhui Lin,François Potus,Sébastien Bonnet,James Iremonger,Jennifer Fu,Jeffrey Mewburn,Danchen Wu,Kimberly J. Dunham-Snary,Anne L. Theilmann,Zhi-Cheng Jing,Charles C.T. Hindmarch,Mark L. Ormiston,Allan Lawrie,Stephen L. Archer +15 more
TL;DR: In this article, the fission mediator dynamin-related protein 1 (Drp1) must be replaced by dynamin related protein 1 in pulmonary arterial hypertension (PAH), a hyperproliferative, apoptosis resistant disease.
Journal ArticleDOI
Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities
Salema Jafri,Mark L. Ormiston +1 more
TL;DR: The identification of common immune mechanisms in systemic hypertension, preeclampsia, and PAH raises the possibility of new therapeutic strategies that target the immune component of hypertension across multiple disorders.